LKKTETQ comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-10. Numbers and descriptions here follow the published literature rather than marketing material.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
| Property | Value | Notes |
|---|---|---|
| Analytical method | LC-MS/MS | Preferred confirmatory technique |
| Appearance | White to off-white powder | Lyophilised form |
| Solubility | Freely soluble in water | Also described in saline |
| Storage temperature | Below -20 °C for powder | Short-term refrigeration for solutions |
| Regulatory status | Prohibited in sport | Listed under peptide hormones |
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
== History == The impact factor was devised by Eugene Garfield, the founder of the Institute for Scientific Information (ISI) in Philadelphia. Impact factors began to be calculated yearly starting from 1975 for journals listed in the Journal Citation Reports (JCR). ISI was acquired by Thomson Scientific & Healthcare in 1992, and became known as Thomson ISI. In 2018, Thomson-Reuters spun off and sold ISI to Onex Corporation and Baring Private Equity Asia. They founded a new corporation, Clarivate, which continued publishing the JCR.
== Nomenclature == The terms chief cell and zymogenic cell are often used without the word "gastric" to name this type of cell. However, those terms can also be used to describe other cell types (for example, parathyroid chief cells). Chief cells are also known as peptic cells.
The share of the world's lead production by the Eastern Bloc increased from 10% to 30%, from 1950 to 1990, with the Soviet Union being the world's largest producer during the mid-1970s and the 1980s, and China starting major lead production in the late 20th century. Unlike the European communist countries, China was largely unindustrialized by the mid-20th century; in 2004, China surpassed Australia as the largest producer of lead. As was the case during European industrialization, lead has had a negative effect on health in China.
Group 1.4.1 is associated with connective tissue disorders including scleroderma (with scleroderma being the most common disorder with an estimated 8-19% of scleroderma patients having PAH), lupus, mixed connective tissue disease, rheumatoid arthritis, and Sjogren's syndrome. Group 1.4.2 is associated with HIV, group 1.4.3 associated with portal hypertension (commonly due to liver cirrhosis), group 1.4.4 associated with congenital heart disease, and 1.4.5 associated with schistosomiasis. In areas where schistosomiasis is prevalent, PAH due to schistosomiasis is believed to be the most prevalent variant of PAH. It is estimated that 5-8% of people with schistosomiasis with liver fibrosis have PAH. Group 1.5 PAH is the variant of PAH that is responsive to vasodilators (calcium channel blockers). The response to vasodilation by definition includes a decrease in the pulmonary arterial pressure of 10 mmHg or more to less than 40 mmHg without a decline in the cardiac output upon infusion of nitrous oxide(vasodilator) during the right heart catheterization. Vasodilator responsive PAH is estimated to be 6.8% of PAH patients in one study, and it is associated with a more favorable prognosis. Group 1.6 PAH includes PAH with features of venous or capillary involvement and is thought to comprise 5-10% of PAH cases. Two conditions, pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis comprise this category. The subcategory is characterized by severe hypoxemia, capillary congestion and prominent post-capillary venule thickening.
== Epidemiology == Accurate epidemiological data on the prevalence of cachexia is lacking due to changing diagnostic criteria and under-identification of people with the disorder. It is estimated that cachexia from any disease is estimated to affect more than 5 million people in the United States. The prevalence of cachexia is growing and estimated at 1% of the population. The prevalence is lower in Asia but due to the larger population, represents a similar burden. Cachexia is also a significant problem in South America and Africa. In people with cancer, prevalence of cachexia was previously reported to range from 11% to 71%. Recent updates show that 33%-51.8% of people with cancer develop cachexia, though estimates vary widely and may be unreliable due to absence of consensus guidelines for diagnosis, variability in cancer populations, and variability in timing of diagnosis. Specifically, the highest rates were seen in older populations as well as those with upper gastrointestinal, colorectal, and lung cancers, respectively. The prevalence increases in advanced cancer stages, affecting up to 80% of terminal cancer cases. The most frequent diseases causing cachexia in the United States are: 1) cancer, 2) chronic heart failure, 3) chronic kidney disease, 4) COPD. Cachexia contributes to significant loss of function and healthcare utilization. Estimates suggest that cachexia accounted for 177,640 hospital stays in 2016 in the United States. Cachexia is considered the immediate cause of death of many people with cancer, estimated between 22 and 40%.
Sources: en.wikipedia.org
Pasteur's research led to Ignaz Semmelweis and Joseph Lister researching the importance of sanitized hands in medical work. In the 1840s, Semmelweis' observations and ideas surrounding sanitary techniques were rejected and his book on the topic condemned by the medical community due to its conflict with the prevailing theory and practice of humorism at the time. After Lister's publications, which supported hand washing and sanitation with germ theory, doctors started sanitizing their hands in the 1870s; mandatory handwashing was not incorporated into common health practice until as late as the 1980s. The discovery of the connection of microorganisms to disease came later in the nineteenth century, when Italian anatomist Filippo Pacini isolated the cholera bacterium Vibrio cholerae in 1854 in Florence during the Asiatic Cholera Pandemic of 1846–63 and clearly linked the presence of the bacterium in the intestinal mucosa of dead cholera patients to the disease. Although Pacini's work was available to the international scientific community via French and English translations, the discovery of the cholera-causing agent is often attributed to the German physician Robert Koch who rediscovered it in 1884. Koch is credited for introducing the science of microorganisms including bacteria to the medical field. Koch, a pioneer in medical microbiology, worked on cholera, anthrax and tuberculosis. In his research into tuberculosis Koch finally proved the germ theory, for which he received a Nobel Prize in 1905.
=== Academic career === Bumpus became a Professor of Medicine in the clinical pharmacology division of Johns Hopkins University School of Medicine, with a secondary appointment in the Department of Pharmacology and Molecular Sciences. She started her own laboratory at Johns Hopkins School of Medicine in 2010 as an Assistant Professor of Medicine and Pharmacology, was promoted to Associate Professor in February 2015, and received Professorship in 2020. Bumpus is known for her research on the metabolism of antiviral drugs used to treat HIV-1 and how genetic variations in drug-processing enzymes may impact these drugs' efficacy. She became Hopkins’ inaugural associate dean of institutional and student equity in 2015 and instituted mentoring programs to expand access to resources and opportunities. After holding that role for two years, in July 2017 she transitioned into a role as senior consulting strategist for Academic and Research Diversity, working with the chief diversity officer to develop and implement diversity and inclusion programs across Johns Hopkins School of Medicine. Bumpus received a Presidential Early Career Award for Scientists and Engineers in 2016. In July 2018, she was named as Associate Dean for Basic Research at Johns Hopkins University School of Medicine.
=== Modern attempts at Carbon 14 dating === Various attempts at radio-carbon analysis were made over the years, with various degrees of success, but with the main effect of pushing back the dates of the first caves to circa 300 CE, and challenging the German classification according to styles and colors schemes. In 1979, a Chinese institute (文物保护科学技术研究所, Wenwu baohu kexue jishu yanjiusuo) carbon-tested caves 63, 47, 13.
Newly formed astatine-211 is the subject of ongoing research in nuclear medicine. It must be used quickly as it decays with a half-life of 7.2 hours; this is long enough to permit multistep labeling strategies. Astatine-211 has potential for targeted alpha-particle therapy, since it decays either via emission of an alpha particle (to bismuth-207), or via electron capture (to an extremely short-lived nuclide, polonium-211, which undergoes further alpha decay), very quickly reaching its stable granddaughter lead-207. Polonium X-rays emitted as a result of the electron capture branch, in the range of 77–92 keV, enable the tracking of astatine in animals and patients. Although astatine-210 has a slightly longer half-life, it is wholly unsuitable because it usually undergoes beta plus decay to the extremely toxic polonium-210. The principal medicinal difference between astatine-211 and iodine-131 (a radioactive iodine isotope also used in medicine) is that iodine-131 emits high-energy beta particles, and astatine does not. Beta particles have much greater penetrating power through tissues than do the much heavier alpha particles. An average alpha particle released by astatine-211 can travel up to 70 μm through surrounding tissues; an average-energy beta particle emitted by iodine-131 can travel nearly 30 times as far, to about 2 mm.
Feminizing hormone therapy, also known as transfeminine hormone therapy, is a form of gender-affirming hormone therapy (GAHT) which change the primary and secondary sex characteristics of transgender people from masculine to feminine. It is one of the two common type of GAHT the other being masculinizing hormone therapy) and is used to treat transgender women and non-binary transfeminine individuals. Some others, in particular intersex people, but also some non-transgender people, take this form of therapy according to their personal needs and preferences. The purpose of the therapy is to cause the development of the secondary sex characteristics of the desired sex, such as breasts and a feminine pattern of hair, fat, and muscle distribution. It cannot undo many of the changes produced by naturally occurring puberty, which may necessitate surgery and other treatments to reverse (see below). The medications used for feminizing hormone therapy include estrogens, antiandrogens, progestogens, and gonadotropin-releasing hormone modulators (GnRH modulators). Feminizing hormone therapy has been empirically shown to reduce the distress and discomfort associated with gender dysphoria in transfeminine individuals.
Sources: en.wikipedia.org
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.
Dry lyophilised powder is normally kept frozen and protected from moisture and light. Dissolved material is handled cold and used promptly to limit degradation.
It is not licensed as a medicine in major markets and is distributed as a research chemical. Sports organisations prohibit its use, and some countries restrict import and supply.
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.